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A B S T R A C T
Background
Hip fracture occurs predominantly in older people, many of whom are frail and undernourished. After hip fracture surgery and
rehabilitation, most patients experience a decline in mobility and function. Anabolic steroids, the synthetic derivatives of the male
hormone testosterone, have been used in combination with exercise to improve muscle mass and strength in athletes. They may have
similar effects in older people who are recovering from hip fracture.
Objectives
To examine the effects (primarily in terms of functional outcome and adverse events) of anabolic steroids after surgical treatment of
hip fracture in older people.
Search methods
We searched the Cochrane Bone, Joint and Muscle Trauma Group Specialised Register (10 September 2013), the Cochrane Central
Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2013 Issue 8), MEDLINE (1946 to August Week 4 2013), EMBASE
(1974 to 2013 Week 36), trial registers, conference proceedings, and reference lists of relevant articles. The search was run in September
2013.
Selection criteria
Randomised controlled trials of anabolic steroids given after hip fracture surgery, in inpatient or outpatient settings, to improve physical
functioning in older patients with hip fracture.
Data collection and analysis
Two review authors independently selected trials (based on predefined inclusion criteria), extracted data and assessed each study’s risk
of bias. A third review author moderated disagreements. Only very limited pooling of data was possible. The primary outcomes were
function (for example, independence in mobility and activities of daily living) and adverse events, including mortality.
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Main results
We screened 1290 records and found only three trials involving 154 female participants, all of whom were aged above 65 years and had
had hip fracture surgery. All studies had methodological shortcomings that placed them at high or unclear risk of bias. Because of this
high risk of bias, imprecise results and likelihood of publication bias, we judged the quality of the evidence for all primary outcomes
to be very low.
These trials tested two comparisons. One trial had three groups and contributed data to both comparisons. None of the trials reported
on patient acceptability of the intervention.
Two very different trials compared anabolic steroid versus control (no anabolic steroid or placebo). One trial compared anabolic steroid
injections (given weekly until discharge from hospital or four weeks, whichever came first) versus placebo injections in 29 “frail elderly
females”. This found very low quality evidence of little difference between the two groups in the numbers discharged to a higher level
of care or dead (one person in the control group died) (8/15 versus 10/14; risk ratio (RR) 0.75, 95% confidence interval (CI) 0.42 to
1.33; P = 0.32), time to independent mobilisation or individual adverse events. The second trial compared anabolic steroid injections
(every three weeks for six months) and daily protein supplementation versus daily protein supplementation alone in 40 “lean elderly
women” who were followed up for one year after surgery. This trial provided very low quality evidence that anabolic steroid may result
in less dependency, assessed in terms of being either dependent in at least two functions or dead (one person in the control group died)
at six and 12 months, but the result was also compatible with no difference or an increase in dependency (dependent in at least two
levels of function or dead at 12 months: 1/17 versus 5/19; RR 0.22, 95% CI 0.03 to 1.73; P = 0.15). The trial found no evidence of
between-group differences in individual adverse events.
Two trials compared anabolic steroids combined with another nutritional intervention (’steroid plus’) versus control (no ’steroid plus’).
One trial compared anabolic steroid injections every three weeks for 12 months in combination with daily supplement of vitamin D
and calcium versus calcium only in 63 women who were living independently at home. The other trial compared anabolic steroid
injections every three weeks for six months and daily protein supplementation versus control in 40 “lean elderly women”. Both trials
found some evidence of better function in the steroid plus group. One trial reported greater independence, higher Harris hip scores
and gait speeds in the steroid plus group at 12 months. The second trial found fewer participants in the anabolic steroid group were
either dependent in at least two functions, including bathing, or dead at six and 12 months (one person in the control group died) (1/
17 versus 7/18; RR 0.15, 95% CI 0.02 to 1.10; P = 0.06). Pooled mortality data (2/51 versus 3/51) from the two trials showed no
evidence of a difference between the two groups at one year. Similarly, there was no evidence of between-group differences in individual
adverse events. Three participants in the steroid group of one trial reported side effects of hoarseness and increased facial hair. The
other trial reported better quality of life in the steroid plus group.
Authors’ conclusions
The available evidence is insufficient to draw conclusions on the effects, primarily in terms of functional outcome and adverse events,
of anabolic steroids, either separately or in combination with nutritional supplements, after surgical treatment of hip fracture in older
people. Given that the available data points to the potential for more promising outcomes with a combined anabolic steroid and
nutritional supplement intervention, we suggest that future research should focus on evaluating this combination.
P L A I N L A N G U A G E S U M M A R Y
Anabolic steroids for improving recovery after hip fracture in older people
Why anabolic steroids might help after a hip fracture
Hip fracture occurs mainly in older people, many of whom are frail. After surgery for their hip fracture, most patients suffer a loss
of muscle mass and strength. Despite rehabilitation, most patients experience a long-term decline in mobility and function. Anabolic
steroids, the synthetic derivatives of the male hormone testosterone, have been used in combination with exercise to improve muscle
mass and strength in athletes. This review considers the evidence for the use of anabolic steroids aimed at improving outcomes after
hip fracture in older people.
Description of the studies included in the review
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We searched the medical literature until September 2013 and found three relevant studies that included a total of 154 women over
the age of 65 years who had had hip surgery. Two studies were conducted in Sweden and one in Canada. The studies tested two
comparisons. One study had three groups and contributed data to both comparisons.
Quality of the evidence
There were only three studies available and all three were small and at high risk of bias. We therefore judged the quality of the evidence
to be very low, which means that we are uncertain how reliable the evidence is.
Summary of the evidence
Two very different studies compared anabolic steroid versus control (no anabolic steroid or placebo). One study conducted in the
hospital ward compared weekly anabolic steroid injections versus placebo injections in 29 “frail elderly females”. This study found
no evidence that anabolic steroid resulted in better function, as measured by numbers discharged to a higher level of care or dead,
or the time to mobilisation. The second study compared steroid injections given every three weeks for six months plus daily protein
supplementation versus daily protein supplementation alone in 40 “lean elderly women”. This study provided some evidence that
anabolic steroids may result in better function, but they may also make no difference or result in worse function. Neither study found
a difference in the incidence of individual adverse events in the two groups.
Two studies compared anabolic steroids combined with another nutritional intervention (’steroid plus’) versus control (no ’steroid plus’).
One study compared anabolic steroid injections every three weeks for 12 months in combination with daily supplement of vitamin D
and calcium versus calcium only in 63 women who were living independently at home. The other study compared anabolic steroid
injections every three weeks for six months and daily protein supplementation versus control in 40 “lean elderly women”. Both studies
found some evidence of better function in the steroid plus group. Pooled mortality data from the two studies showed no difference
between the two groups at one year. Similarly, there was no evidence of between-group differences in individual adverse events. Three
participants in the steroid group of one study reported side effects of hoarseness and increased facial hair. The other study reported
better quality of life in the steroid plus group. None of the studies reported on patient acceptability of the intervention.
Conclusions
The quality of the evidence was very low, meaning that we are very uncertain about the direction and size of effect. Thus we are unable
to say if anabolic steroids, either separately or in combination with nutritional supplements, improve recovery after hip fracture surgery
in older people. Given that the results available point to the potential for more promising outcomes with a combined anabolic steroid
and nutritional supplement intervention, we suggest that future research should focus on evaluating this combination.
B A C K G R O U N D
Description of the condition
Fracture of the proximal femur (known widely as hip fracture) is a
common cause of morbidity and mortality in older people. About
40% to 50% of women and 13% to 22% of men are at risk of
having an osteoporotic fracture in their lifetime (Dennison 2006).
With the rise in life expectancy, the prevalence of hip fracture
is expected to increase (Cooper 1992; Gullberg 1997). There is
worldwide variation in the incidence of hip fracture. While it is
already an established health problem in the West, it is increasingly
recognised as a growing problem in Asia (Mithal 2009).
Surgical management is the mainstay of the treatment for hip frac-
ture. This is generally followed by inpatient rehabilitation, with
or without extension to an outpatient rehabilitation programme
(Marks 2003). Despite treatment, functional recovery after hip
fracture is often incomplete, with many people who were walking
independently before their hip fracture losing their independence
afterwards (Osnes 2004). This negatively impacts on their quality
of life (Adachi 2001). By six to 12 months after a hip fracture,
between 22% and 75% of people have not recovered their pre-
fracture ambulatory or functional status (Cummings 1988; Koval
1995). People sustaining hip fracture use extensive health system
resources (Braithwaite 2003), and many patients require contin-
ued support and care services. After their initial treatment, people
who have had a hip fracture are at high risk for re-hospitalisation
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(Wolinsky 1997), refracture (Johnell 1985) and institutionalisa-
tion (Rosell 2003; Tajeu 2013). Older adults have five- to eight-
fold increased risk of dying during the first three months after hip
fracture (Haentjens 2010). There is also some evidence that func-
tional recovery after hip fracture is the main determinant of long-
term mortality (Dubljanin-Raspopovi 2013).
Description of the intervention
Following surgical treatment of hip fracture, a wide range of thera-
pies are used to promote functional recovery (SIGN 2009). Some
of these have specific goals such as restoration of mobility and in-
dependence in basic activities of daily living. This review focuses
on the use of anabolic steroids for restoring and maintaining func-
tion after hip fracture surgery.
Anabolic steroids are a group of synthetic hormones, related to the
male hormone testosterone, that promote the storage of protein
and the growth of tissue (anabolism) (Dorland 2007). Their use
has been demonstrated to have a positive effect in the treatment
of diverse clinical conditions, including the treatment of anaemia
in renal disease patients (Navarro 2002; Teruel 1996), osteoporo-
sis (specifically bone density), cachexia (muscle wasting) in peo-
ple with chronic illness (Johns 2009), and improving muscle mass
and strength in older people (Snyder 1999). Women show an age-
related decline in endogenous androgen levels, which might influ-
ence the development of osteoporosis (Zofkova 2000). A double-
blind randomised controlled trial showed better mobility and less
pain in people with vertebral fractures after treatment with an-
abolic steroids compared with a vitamin D analogue, alphacalcidol
(Lyritis 1994).
Anabolic steroids come in different preparations, which can be
given various ways (e.g. orally, skin patches, intramuscular injec-
tions), started at different times (prior to, or at any stage of recov-
ery after hip fracture surgery) and can be administered for differ-
ent lengths of time.
How the intervention might work
Patients with hip fractures are often elderly, frail and undernour-
ished (Bachrach-Lindström 2000; Lumbers 2001). They may un-
dergo a catabolic state (Patterson 1992), which leads to chronic
muscle wasting and reduced muscle strength. This can affect mo-
bility and result in falls. Loss of muscle mass and lean body weight
contribute to generalised weakness, an impaired immune response
and slower wound healing. Anabolic steroids provide some benefit
in other conditions associated with increased catabolic rates such
as burns, chronic obstructive airway disease and acquired immune
deficiency syndrome (AIDS) (Berger 1996).
There is also good reason to combine the use of anabolic steroids
with nutritional supplementation. Protein energy malnutrition oc-
curs in 30% to 50% of people who sustain a hip fracture (Lumbers
1996; Ponzer 1999). Postoperative hip fracture rehabilitation is fa-
cilitated by improving the nutritional intake of the patient (Delmi
1990). A Cochrane review concluded that some evidence exists
for the beneficial effects of nutritional supplementation after hip
fracture (Avenell 2006). There is some evidence that combining
testosterone and nutritional supplementation for undernourished
older people reduces both the number of people hospitalised and
the duration of hospital admissions (Chapman 2009).
Adverse effects, often dose-related, from anabolic steroids include
changes in voice, growth of facial hair in women, hair loss, acne,
oedema, thromboembolic events and liver damage.
Why it is important to do this review
Despite advances in surgical treatments, hip fractures continue to
have a large impact on older people and society because they often
result in disability and institutionalisation (Fierens 2006; Osnes
2004). Anabolic steroids may have a role in improving outcomes
and recovery, and allowing greater independence in these patients.
It is important to assess the evidence for the use of these drugs in
this predominantly elderly and frail population.
O B J E C T I V E S
To examine the effects (primarily in terms of functional outcome
and adverse events) of anabolic steroids after surgical treatment of
hip fracture in older people.
The following main comparisons were intended, set in the context
of usual or conventional care.
• Anabolic steroid versus no anabolic steroid or a placebo
control.
• Anabolic steroid in conjunction with other intervention
(either nutrition or exercise or both) versus no anabolic steroid
plus same other intervention or a placebo control.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials of anabolic steroid treat-
ment following surgery for hip fracture. We planned also to in-
clude trials that used quasi-randomisation (e.g. allocation by date
of birth or hospital record number) or cluster randomisation (e.g.
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by hospital ward). The failure to use an intention-to-treat approach
to analysis was not a reason for exclusion.
Types of participants
We considered older people with any type of hip fracture that was
surgically treated. It was anticipated that a large proportion of these
people would be older than 65 years of age. We did not exclude
trials that included younger participants if the mean age minus one
standard deviation was greater than 65 years. Participants younger
than 65 years, or with multi-trauma or with pathological fractures,
would have been included provided they made up less than 25%
of the total sample size, and there was adequate randomisation of
these participants to intervention and control groups.
Types of interventions
The intervention assessed was anabolic steroids, administered en-
terally (orally, nasogastric or via percutaneous gastrostomy tubes),
parenterally (intramuscular routes) or via alternative routes such as
transdermal. The intervention could start prior to or at any stage of
recovery after hip fracture surgery, but interventions that were pre-
surgical only were excluded. The duration of administration could
vary and it was acceptable for it to continue until the end of the
rehabilitation phase. We compared the administration of anabolic
steroids with the provision of no intervention or a placebo inter-
vention. It was envisaged that usual or conventional care would
be provided to all trial participants. Such care, as described below,
could comprise nutrition or exercise or both.
We included the following comparisons, set in the context of usual
or conventional care.
1. Anabolic steroid versus no anabolic steroid or a placebo
control. This included studies where nutrition or exercise or both
were provided to both groups in the comparison.
2. Anabolic steroid plus ’other intervention’, where this was
either nutrition or exercise or both, versus no anabolic steroid
plus same other intervention or a placebo control.
Types of outcome measures
Primary outcomes
The primary outcome was function: for example, independence
in mobility and activities of daily living. We gave preference to val-
idated, patient-reported outcome measures. We also sought data
on adverse events including mortality, hospital readmission and
complications from the use of anabolic steroids.
Secondary outcomes
Secondary outcomes were patients’ perceived quality of life, adher-
ence and acceptability of the intervention, objective assessments
of body composition, nutritional indices, muscle strength and the
use of resources such as length of hospital stay.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Bone, Joint and Muscle Trauma Group
Specialised Register (10 September 2013), the Cochrane Cen-
tral Register of Controlled Trials (The Cochrane Library, 2013
Issue 8), MEDLINE (1946 to August Week 4 2013), MED-
LINE In-Process & Other Non-Indexed Citations (9 September
2013) and EMBASE (1974 to 2013 Week 36). We also searched
Current Controlled Trials and the WHO international Clinical
Trials Registry Platform for ongoing and recently completed trials
(September 2013). We did not impose any restrictions based on
language or publication status.
In MEDLINE (OvidSP), the subject specific search was com-
bined with the sensitivity-maximizing version of the Cochrane
Highly Sensitive Search Strategy for identifying randomised trials
(Lefebvre 2011). Search strategies for the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL), MEDLINE and EMBASE
are shown in Appendix 1.
Searching other resources
We assessed the American Orthopaedic Trauma Association’s
annual meetings (1996 to 2012) by handsearching the table of
contents of the meeting proceedings. We also searched reference
lists of relevant articles.
Data collection and analysis
The intended methodology for data collection and analysis was
described in our published protocol (Farooqi 2010).
Selection of studies
Two review authors (VF and MvdB) independently screened titles
and abstracts of records identified from database searches for pos-
sible inclusion. We retrieved the full text of potentially relevant
citations. From the full text, we selected trials that met the selec-
tion criteria for inclusion. We sought further information from
trial authors where necessary. A third author (MC) moderated any
disagreement. We documented the reasons for exclusion.
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Data extraction and management
Two review authors (VF and MvdB) independently performed
data extraction using a piloted form. The data collected included
study design characteristics, study population, interventions, out-
come measures, and length of follow-up. We attempted to contact
trial authors for clarification when necessary. Disagreements were
resolved by a third review author (MC).
Assessment of risk of bias in included studies
Two review authors (VF and MvdB) independently assessed risk
of bias using a piloted version of The Cochrane Collaboration’s
’Risk of bias’ tool (Higgins 2011). Disagreements were resolved by
discussion. We assessed random sequence generation, allocation
concealment, blinding of participants and personnel, blinding of
outcome assessment, incomplete outcome data, selective outcome
reporting and other biases, including those associated with major
baseline imbalance and early stopping. We rated each domain as
either ’low risk’; ’unclear risk’ or ’high risk’ of bias.
Measures of treatment effect
We analysed results both at short-term (six months or less) and
longer-term (more than six months) intervals. We calculated risk
ratios (RRs) with 95% confidence intervals (CIs) for dichotomous
outcomes. We calculated mean differences with 95% CIs for con-
tinuous outcomes. We had planned to use standardised mean dif-
ferences for pooling continuous outcomes based on differences in
scores or scales.
Unit of analysis issues
The unit of randomisation in these trials was the individual pa-
tient. However, we would have considered randomised trials where
the unit of randomisation was another entity, such as a hospital
ward. If possible, appropriate adjustments would have been made
before presenting data from such trials if the trial authors had not
adjusted for clustering. We planned to seek advice on the inter-
pretation and presentation of the results from such trials from the
statistical editors of the Cochrane Bone, Joint and Muscle Trauma
Review Group.
Dealing with missing data
We attempted to contact the authors of included trials for missing
data. Where appropriate, we intended to perform intention-to-
treat analysis to include all people randomised. However, where
drop-outs were identified, the actual denominators of participants
contributing data at the relevant outcome assessment were used.
When possible, in future updates, we will investigate the effect of
drop-outs and exclusions by conducting worst- and best-case sce-
nario sensitivity analyses. The ’best-case’ scenario is when all par-
ticipants with missing outcomes in the experimental intervention
group are assigned a good outcome, and all those with missing
outcomes in the control intervention group a bad outcome; the
’worst-case’ scenario is the converse. We will continue to be alert
to potential mislabelling or non-identification of standard errors
and standard deviations. Additionally, unless missing standard de-
viations can be derived from CIs, P values or standard errors, we
will not assume values in order to present these in the analyses.
Assessment of heterogeneity
We planned to assess heterogeneity by visual inspection of the
forest plot (analysis) and consideration of the Chi² test for het-
erogeneity and the I² statistic (Higgins 2003). We interpreted I²
values as follows: 0% to 40% might not be important; 30% to
60% may represent moderate heterogeneity; 50% to 90% may
represent substantial heterogeneity; 75% to 100% considerable
heterogeneity (Deeks 2011).
Assessment of reporting biases
If at least 10 trials had contributed data to a forest plot, we would
have considered preparing a funnel plot to assess publication bias.
We investigated selective outcome reporting by comparing the
study outcomes with those routinely presented for similar studies
and also by comparing the methods section with the results re-
ported in the trials.
Data synthesis
Where considered appropriate, we pooled results of comparable
groups of trials. We used the fixed-effect model and 95% CIs. We
would have considered using the random-effects model, especially
where there was unexplained heterogeneity. It was anticipated that
we would pool data even if heterogeneity was high. For continuous
outcomes, where outcomes were reported using different scales or
instruments but assessing the same dimension, the results were
to be pooled using the standardised mean difference. Mindful of
unit of analysis issues, we intended to pool the data from cluster-
randomised trials using the generic inverse variance.
Subgroup analysis and investigation of heterogeneity
If sufficient data are available in future, we will conduct sub-
group analyses to determine whether the primary outcomes vary
according to gender and route of steroid administration. We will
use the test for subgroup differences available in Review Manager
(RevMan 2014) to determine if the results for subgroups are sta-
tistically significantly different.
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Sensitivity analysis
Had sufficient data been available, we would have performed sen-
sitivity analyses to explore the effects of important sources of bias,
such as whether allocation was concealed, in the included studies.
Assessment of the quality of the evidence
We used the GRADE approach to assess the quality of evidence
related to the primary outcomes listed in the Types of outcome
measures (Schunemann 2011, section 12.2). Where there is suffi-
cient evidence in future to merit the preparation of ’Summary of
findings’ tables, we will develop these for the main comparisons.
R E S U L T S
Description of studies
Results of the search
The search was completed in September 2013. We screened a
total of 1290 records from the following databases: Cochrane
Bone, Joint and Muscle Trauma Group Specialised Register (8
records); Cochrane Central Register of Controlled Trials (CEN-
TRAL) (113), MEDLINE (598), EMBASE (480), the WHO
International Clinical Trials Registry Platform (27) and Current
Controlled Trials (64).
We identified six potentially eligible studies, published in 10
reports. On full review of their texts, we included three trials
(Hedstrom 2002 (two reports); Sloan 1992; Tidermark 2004 (four
reports)) and excluded two (Beringer 1986; Naessen 2008). One
trial (NCT00280267), while completed, has yet to be published
(see the Characteristics of ongoing studies).
A flow diagram summarising the study selection process is shown
in Figure 1.
Figure 1. Study flow diagram
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Included studies
We included three trials (Hedstrom 2002; Sloan 1992; Tidermark
2004), all of which investigated the effects of anabolic steroids on
recovery from hip fracture surgery in older people aged 65 years
or over. The three trials included a total of 154 female participants
(Table 1). Sloan 1992 also included eight males but provided only
a brief summary of the results of this small subgroup. For com-
pleteness, we present the results for adverse events for this sub-
group in this review.
Summaries of the three trials are given below. For further details,
please see the Characteristics of included studies.
Hedstrom 2002 compared nandrolone decanoate (steroid) at the
dose of 25 mg intramuscularly every third week for one year and
a daily supplement of 1alpha-hydroxylated vitamin D3 (0.25 g)
plus calcium (500 mg) versus calcium (500 mg) alone (control
group). This study, conducted in Sweden, included 63 women
(mean age 80.5 years) who were living independently at home
after hip fracture surgery. Follow-up assessments were at 3, 6, 9
and 12 months.
Sloan 1992 included 31 women (mean age 82 years) who had
been treated surgically for hip fracture. They compared weekly
nandrolone decanoate (steroid) intramuscular injections 2 mg/kg
versus a placebo group. The steroid injections were given weekly
until discharge from hospital or four weeks, whichever came first.
Follow-up assessments were weekly until four weeks or discharge,
whichever came first.
Tidermark 2004 was conducted in Sweden and involved 60
women (mean age 83 years) who had hip fracture surgery. The
purpose was to evaluate the effects of a protein-rich liquid sup-
plementation, alone or in combination with the anabolic steroid
nandrolone decanoate. The participants were randomised to the
following groups.
1. Steroid plus group: nandrolone decanoate (Deca-Durabol
25 mg every three weeks) + protein-rich formula (Fortimel 200
ml/day, 20 g protein/day) + daily calcium (1 g) and vitamin D
(CalchichewD3 800 IE).
2. Control group (protein supplementation): protein-rich
formula (Fortimel) + daily calcium + vitamin D (doses as above).
3. Control group: daily calcium and vitamin D (doses as
above).
Follow-up assessments were at six and 12 months. The Tengstrand
2007 publication was a post hoc analysis of Tidermark 2004 and
thus not a separate trial.
Excluded studies
We excluded two studies. The primary reason for excluding
Beringer 1986, which compared the relative effects on calcitonin
secretion of anabolic steroid (Stanozolol) versus oral calcium in
20 women with hip fracture, was the lack of a no treatment con-
trol. We excluded Naessen 2008 because it included only healthy
women without hip fracture. For more details, please see the
Characteristics of excluded studies.
Risk of bias in included studies
Summaries of our risk of bias assessment of the included studies
are presented in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Allocation
None of the trials gave details of their method of random sequence
generation and we therefore judged all three trials as being at un-
clear risk of bias for this item.
Two trials (Hedstrom 2002; Tidermark 2004) used sealed en-
velopes; Tidermark 2004 further described these as opaque and
was thus considered to be at low risk of selection bias relating to
successful concealment of allocation. The risk of selection bias in
Hedstrom 2002 was judged as unclear. The same applied for Sloan
1992, which did not disclose their method of allocation conceal-
ment.
Blinding
Hedstrom 2002 did not describe blinding of either participants,
investigators or outcome assessors and we judged this trial to be
at high risk of both performance and detection bias. Sloan 1992
did not provide details of blinding but we considered this trial to
be at low risk of performance and detection bias given that it was
clearly reported to be a double-blind, placebo-controlled study.
Tidermark 2004 was ’open label’ and at high risk of performance
bias; however, although it did not describe blinding, there was
independent outcome assessment, which we judged put it at ’un-
clear’ rather than high risk of detection bias.
Incomplete outcome data
Only Tidermark 2004 was at low risk of attrition bias as it used
an intention-to-treat analysis and gave a participant flow diagram,
illustrating losses at 12 months follow-up. While both Hedstrom
2002 and Sloan 1992 documented the reasons for drop-outs in
their trials, the reporting of losses was incomplete and unclear in
Hedstrom 2002. The added failure to add in the denominators in
the tables makes this trial at high risk of attrition bias. Similarly,
we judged Sloan 1992 as being at high risk of attrition bias, reflect-
ing both the large percentage of participants with missing data at
four weeks (39% = 12/31) (patients being discharged from their
inpatient stay) and an imbalance between the two groups in those
available at four weeks (12/16 versus 7/15). This is a consequence
of a flawed study design where no efforts were made to obtain
post-discharge outcomes.
Selective reporting
Published trial registration information or protocols were not avail-
able for any of the three trials. However, all the outcomes that
were listed in the methods sections were reported in the results.
All three trial reports had aspects that appeared to indicate post
hoc reporting decisions and thus we judged them as being unclear
for reporting bias. Hedstrom 2002 reported functional outcomes
using the Katz Index but provided the median and range and it
was not clear if they intended to report the three-month results.
Tidermark 2004 used the same scale (the Katz Index) as Hedstrom
2002 but did not report means and standard deviations. Instead
they chose to present the results in a graph format without giv-
ing actual values. They also reported significant differences among
groups in terms of the quality of life scores using EQ-5D index
but again presented the results as a graph. We judged Sloan 1992
to be at unclear risk of bias because of the incomplete reporting
of the results of the male participants and the lack of clarity about
whether they intended to report males and females separately from
the outset.
Other potential sources of bias
We judged Hedstrom 2002 and Tidermark 2004 to be at low risk
of other bias, specifically bias relating to major imbalances in base-
line characteristics and early stopping. Baseline characteristic data
for Sloan 1992 provided for 29 of the 31 female participants (none
were provided for the male participants) showed the participants
in the steroid group had lower functional ability and were more
dependent in activities of daily living than in the placebo group.
We judged this trial as being at high risk of other bias.
Effects of interventions
Anabolic steroid versus no anabolic steroid or a
placebo intervention
Sloan 1992 compared anabolic steroid with placebo interven-
tion, reporting results for 17 participants at four weeks follow-up.
Tidermark 2004 compared anabolic steroid and protein supple-
mentation versus protein supplementation alone, reporting results
for 35 participants at 6 and 12 months follow-up. The large dif-
ference in the timing of follow-up of these two trials meant that
pooling data for common outcomes was inappropriate.
Primary outcomes
Functional independence
One person in the control group of Sloan 1992 died in hospital.
Similar numbers of participants in the two groups of Sloan 1992
were discharged to a higher level of care. The results of the com-
bined outcome of death or discharge to a higher level of care (’more
dependent or dead at hospital discharge’) are shown in Analysis
1.1 (8/15 versus 10/14, risk ratio (RR) 0.75, 95% CI (confidence
interval) 0.42 to 1.33; P = 0.32).
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One person in the control group (nutrition only) of Tidermark
2004 died within one year. Tidermark 2004 based their functional
assessment on the results of the Katz Index and used graphs to
display the results grouped by independence in five or all six activ-
ities of daily living functions versus dependence in bathing and at
least one other function. Fewer participants in the anabolic steroid
group were either dependent in at least two functions or dead at
six months (0/17 versus 3/19; RR 0.16, 95% CI 0.01 to 2.87; P =
0.21) and at 12 months (1/17 versus 5/19; RR 0.22, 95% CI 0.03
to 1.73; P = 0.15) (Analysis 1.2); neither result was statistically
significant.
Although the anabolic steroid group in Sloan 1992 took a longer
time to stand with support (steroid: 3.1 days versus control: 2.3
days; MD 0.80 days, 95% CI -0.59 to 2.19 days; P = 0.26), and
five days longer on average to mobilise independently (steroid:
14.5 days versus control: 9.3 days; MD 5.20 days, 95% CI -1.68
to 12.08 days; P = 0.14), neither of the differences between the
two groups was statistically significant (Analysis 1.3).
Adverse events
One participant in the control group of each trial died within the
follow-up period (Analysis 1.4). Since the number of participants
experiencing an adverse event was not available, details of the
individual events are described below and displayed in Analysis
1.5. This is restricted to female participants only.
Sloan 1992 withdrew one participant in the steroid group because
of the doubling of the serum liver enzymes after their second
injection (liver function tests were normal within the next week)
and one participant in the placebo group because of nightmares.
Of the 15 remaining in the steroid group, there was one case of
pulmonary embolism and two cases of delirium within one week
post-surgery. In the 14 participants in the control group, there was
one case of deep venous thrombosis, one gastrointestinal bleed and
two participants developed post-operative depression. There was
a total of 10 units of blood transfused to participants in the steroid
group and seven units to participants in the placebo group.
Of the eight male participants in Sloan 1992, one of the three
steroid group participants required a transurethral prostatectomy
after developing a urinary obstruction. One participant in each
group became depressed. In the control group, one participant
had a deep venous thrombosis and one had a syncopal event.
In Tidermark 2004, fracture healing complications were recorded
in six participants of the steroid group versus four of the control
group; and urinary tract infection was reported for five versus three
participants. A slight and transient elevation of serum calcium was
noted in six participants of the steroid group.
Secondary outcomes
Patients’ perceived quality of life
Tidermark 2004 captured patient-rated health-related quality of
life (HRQoL) during the week preceding the injury using the Eu-
roQol (EQ-5D). They performed a logistic regression analysis in
order to evaluate factors of importance for changes in the HRQoL.
Randomisation to the combined anabolic steroid and protein sup-
plement group (steroid group) was reported to be associated with
an increased odds ratio for improved HRQoL at the end of the
six month intervention period (P < 0.05). These results were pre-
sented as a graph only and no baseline values, changes in scores
or means or standard deviations were given in textual format or a
table.
Adherence and acceptability of the intervention
All but one participant in the steroid group of Sloan 1992 received
at least four doses of the anabolic steroid. In Tidermark 2004,
one patient withdrew consent following randomisation, but prior
to receiving the intervention. The intramuscular nandrolone in-
jections were administered by a research nurse in patients’ own
homes while the compliance regarding the protein-rich formula
and calcium/vitamin D was verified with interviews and logbooks.
The adherence for steroid administration was 100%.
Neither trial recorded patient acceptability of the intervention nor,
in Sloan 1992, of the weekly injection.
Objective assessments of body composition
On average, participants in the steroid group in Sloan 1992 were
lighter and had lower lean body mass (measured in three ways)
and smaller mid-arm muscle circumference than participants on
placebo group at baseline; a difference that persisted in the follow-
up data (Analysis 1.6).
Tidermark 2004 showed smaller declines in body weight and lean
body mass (measured using dual energy X-ray absorptiometry) at
12 months in the steroid group; the differences between the two
groups did not reach statistical significance (Analysis 1.7).
Nutritional indices
Both Sloan 1992 and Tidermark 2004 reported changes in al-
bumin as a marker for nutritional improvement during recovery
from hip fracture. Neither trial found a difference between the
two groups (Analysis 1.8). None of the differences in three other
nutritional indices reached statistical significance in Sloan 1992.
Muscle strength
Sloan 1992 and Tidermark 2004 both reported on hand grip
strength as a measure of muscle strength. Neither study found a sta-
tistically significant difference between the groups at final follow-
up (four weeks: Sloan 1992; one year: Tidermark 2004) (Analysis
1.9).
Use of resources such as length of hospital stay
With the exception of length of hospital stay data, neither trial
reported resource use or cost outcomes. In Sloan 1992, the steroid
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group stayed in hospital an average of five days longer than those
in the placebo group (steroid: 45 days versus control: 40 days; MD
5.00 days, 95% CI -11.46 to 21.46 days; P = 0.55); the difference
between the two groups was not statistically significant (Analysis
1.10). Tidermark 2004 reported that the difference in length of
hospital stay in the first year after surgery was not significant (me-
dian (range): 18 (8 to 51) days versus 20 (5 to 356) days).
Anabolic steroid plus other intervention (’steroid
plus’) versus no anabolic steroid plus some other
intervention or a placebo control
The two trials (Hedstrom 2002; Tidermark 2004) in this compar-
ison differed in their co-interventions. Hedstrom 2002 compared
anabolic steroid plus vitamin D plus calcium (steroid plus group)
with calcium alone (control group); and reported results for an es-
timated 44 participants at 12 months follow-up. Tidermark 2004
compared anabolic steroid and protein supplementation (steroid
plus group) versus no steroid or protein supplementation (control
group); and reported results for 34 patients at follow-up.
Primary outcomes
Functional independence
Hedstrom 2002 used the Katz index to assess the level of indepen-
dence in activities of daily living. Both the steroid plus group and
the control group had equal medians at both six and 12 months
(median = 6); however, the range was narrower and towards im-
proved independence at 12 months in the steroid plus group (re-
ported P = 0.05; Analysis 2.1).
Tidermark 2004 based their functional assessment on the results
of the Katz Index and used graphs to display the results grouped
by independence in five or all six activities of daily living func-
tions versus dependence in bathing and at least one more func-
tion. Fewer participants in the anabolic steroid group were either
dependent in at least two functions, including bathing, or dead at
six months (0/17 versus 8/16; RR 0.06, 95% CI 0.00 to 0.89; P
= 0.04) and 12 months (1/17 versus 7/18; RR 0.15, 95% CI 0.02
to 1.10; P = 0.06) (Analysis 2.2). One person in the control group
had died within 12 months.
Hedstrom 2002 reported significantly higher Harris hip scores in
the steroid plus group at six months (median 86 versus 72; reported
P = 0.006) and 12 months (median 88.5 versus 79; reported P =
0.04) (Analysis 2.3), suggesting a better outcome for this group.
Gait speed
Hedstrom 2002 reported significantly higher gait speeds in the
steroid plus group at both six months (P = 0.007) and 12 months
(P = 0.009) post-intervention (Analysis 2.4).
Adverse events
Hedstrom 2002 reported four deaths, two in each group, up to 12
months follow-up (Analysis 2.5). Seven participants, four in the
steroid plus group and three in the control group developed pseu-
darthrosis or avascular necrosis and underwent arthroplasty sub-
sequently (Analysis 2.6). Three participants of the steroid group
had side effects such as hoarseness or increased facial hair.
In Tidermark 2004, one person died in the control group. Frac-
ture healing complications were recorded in six participants of
the steroid plus group versus seven of the control group; and uri-
nary tract infection was reported for five versus three participants
(Analysis 2.6). A slight and transient elevation of serum calcium
was noted in six participants of the steroid group. Two participants
in the steroid group developed deep infection.
Secondary outcomes
Patients’ perceived quality of life
Tidermark 2004 captured patient-rated HRQoL during the week
preceding the injury using the EuroQol (EQ-5D). A logistic re-
gression analysis was performed in order to further evaluate factors
of importance for changes in the HRQoL. Randomisation to the
steroid plus group was associated with an increased odds ratio for
improved HRQoL at the end of the six month intervention period
(P < 0.05). These results were presented as a graph only with no
presentation of actual values, means or standard deviations.
Adherence and acceptability of the intervention
Hedstrom 2002 stated that participants who discontinued treat-
ment “were analysed by intention-to-treat”, but gave only limited
information relating to adherence. Four people, two in each group,
declined to participate in the study after their hip surgery and two
others (group not stated) appeared to have stopped due to ill health
at seven and eight months. There were several others lost to follow-
up, including four deaths. Aside from one person allocated in the
steroid plus group who withdrew her consent, Tidermark 2004 re-
ported 100% compliance for the anabolic steroid administration
and that, based on interviews and a logbook, there appeared to be
“no indications of inadequate compliance” regarding the protein
supplementation or vitamin D and calcium interventions.
Neither trial reported directly on the acceptability of the interven-
tion to the participants.
Objective assessments of body composition
The data for the various measures relating to body composition
presented in Hedstrom 2002 are shown in Analysis 2.7. No mea-
sures of variability were reported. The differences between the two
groups in the changes in the body mass index or skinfold thickness
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between groups at six and 12 months were generally statistically
not significant. There was a significantly greater increase in muscle
volume in the steroid plus group at six months (P = 0.004) and
at 12 months (P = 0.002) in the non-operated leg. The operated
leg results also favoured the steroid plus group (P = 0.01 at both
follow-ups). Hedstrom 2002 calculated relative muscle mass to
demonstrate that these differences were not due to intracellular
fluid accumulation, a known side-effect of anabolic steroid treat-
ment.
Tidermark 2004 found no statistically significant differences be-
tween the two groups in the decline in body weight and lean body
mass (measured using dual energy X-ray absorptiometry) at 12
months (Analysis 2.8).
Nutritional indices
Tidermark 2004 found no statistically significant difference be-
tween the two groups in changes in albumin at 12 months
(Analysis 2.9).
Muscle strength
Tidermark 2004 reported on hand grip strength as a measure of
muscle strength. Although the results favoured the steroid plus
group, the difference between the two groups in grip strength at
one year did not reach statistical significance (P = 0.16) (Analysis
2.10).
Use of resources such as length of hospital stay
With the exception of length of hospital stay data for Tidermark
2004, neither trial reported resource use or costs outcomes.
Tidermark 2004 reported that the difference in length of hospi-
tal stay in the first year after surgery was not significant (median
(range): 18 (8 to 51) days versus 27 (5 to 197) days).
D I S C U S S I O N
Summary of main results
The aim of this review was to evaluate the effect of anabolic steroids
on functional outcome after surgical treatment of hip fracture
in older people. We included three heterogeneous randomised
controlled trials, involving a total of 154 female patients after
hip fracture surgery. As well as being small trials, all three had
methodological shortcomings that placed them at high or unclear
risk of bias. One trial had three groups and contributed data to
the two main comparisons listed in our Objectives. Reflecting the
high risk of bias of the included trials, the imprecision of the results
and the risk of publication bias, we concluded that the evidence
for all primary outcomes is of very low quality, which means that
we are very uncertain about the results.
Anabolic steroid versus control (no anabolic steroid
or a placebo intervention)
The two trials that compared anabolic steroid with control tested
this in very different settings and patient populations. Sloan 1992,
a ’pilot’ trial, compared anabolic steroid injections versus placebo
injections given weekly until discharge from hospital or four weeks,
whichever came first, in 31 “frail elderly females” (mean age 82
years). Tidermark 2004 compared anabolic steroid injections ev-
ery three weeks for six months and daily protein supplementa-
tion versus daily protein supplementation alone, in 40 “lean el-
derly women” (mean age 82 years) who were followed up for one
year post-surgery. These differences and the incompatible outcome
measurement, including timing of follow-up, precluded pooling
of data. Sloan 1992 provided very low quality evidence of little
difference between the two groups in the combined outcome of
discharge to a higher level of care or dead, in the restoration of
mobility (time to weight-bear; time to mobilise independently)
or in individual adverse events. It is plausible that the tendency
in the steroid group to take longer to weight-bear and walk inde-
pendently could relate to the poorer pre-fracture function of this
group. One participant in this group withdrew after a doubling of
serum liver enzymes. Tidermark 2004 provided very low quality
evidence that anabolic steroid may result in less dependency, as-
sessed in terms of being either dependent in at least two functions
or dead at six and 12 months, but the result was also compatible
with no difference or an increase in dependency. Tidermark 2004
found no evidence of between-group differences in adverse events
(fracture healing complications; urinary tract infection). Both tri-
als reported nearly complete compliance with the administration
of the steroid injection. Neither trial reported on patient accept-
ability of the intervention.
Anabolic steroid plus nutritional co-intervention
(steroid plus) versus control (no anabolic steroid plus
nutritional co-intervention)
Although the study design and patient population of two trials
that compared anabolic steroid plus a nutritional co-intervention
versus control were sufficiently similar to warrant pooling, this was
possible only for one-year mortality. Hedstrom 2002 compared
anabolic steroid injections every three weeks for 12 months and a
daily supplement of vitamin D versus control in 63 women (mean
age 80.5 years) who were living independently at home after hip
fracture surgery. Tidermark 2004 compared anabolic steroid in-
jections every three weeks for six months and daily protein supple-
mentation versus control in 40 “lean elderly women” (mean age
83 years) who were followed up for one year post-surgery.
Although data could not be pooled, both trials found some very
low quality evidence of better function in the steroid plus group.
One trial reported a narrower distribution of Katz scores towards
greater independence in the steroid plus group at 12 months. The
same trial reported significantly higher Harris hip scores and gait
speeds for both six months and 12 months follow-up times in the
steroid plus group. The second trial found fewer participants in
13Anabolic steroids for rehabilitation after hip fracture in older people (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the anabolic steroid group were either dependent in at least two
functions, including bathing, or dead at six months and 12 months
(one person in the control group had died within 12 months).
Pooled mortality data from the two trials showed no evidence of
a difference between the two groups at one year. Similarly, there
was no evidence of between-group differences in adverse events.
However, Hedstrom 2002 reported that three participants (9.4%)
of the steroid group had side effects (hoarseness or increased facial
hair) of anabolic steroids while Tidermark 2004 reported better
quality of life in the steroid plus group. Tidermark 2004 also
reported nearly complete compliance with the administration of
the steroid injection. Neither trial reported on patient acceptability
of the intervention.
Overall completeness and applicability of
evidence
All three trials were small and pooling of data was undertaken for
one outcome (mortality) from two trials only.
Since hip fractures occur predominantly in older females, the re-
striction to older females in the three trials is acceptable although
it limits applicability. A further limitation is that all three trials
excluded patients with severe cognitive impairment or dementia,
which is present in around 25% to 33% of the typical hip fracture
population. Other considerations include that Sloan 1992 was an
inpatient study, with a more representative population in the hos-
pital setting, whereas Hedstrom 2002 was an outpatient trial that
included only people who were able to live independently in their
own home after recovery from hip fracture surgery.
As well as differing in their populations, the trials differed in
their interventions, co-interventions, control groups, durations
and outcome assessment. Sloan 1992 used weekly nandrolone de-
canoate intramuscular injections at a dose of 2 mg/kg until dis-
charge or four weeks, whichever came first. In contrast, Hedstrom
2002 and Tidermark 2004 used 25 mg intramuscular nandrolone
injections every three weeks for 12 and six months, respectively.
These two trials also used steroids in combination with either pro-
tein supplement or Vitamin D. Combining interventions adds
complexity to the interpretation as interaction between interven-
tions could be responsible for the effects, or the effect could be
solely attributed to the nutritional intervention other than the an-
abolic steroid. The variability in the duration and dosages of an-
abolic steroids makes it difficult to establish what doses should be
tested in future studies. Cummings 1988 and Koval 1995 have
documented the deterioration in function following hip fracture
and the deterioration in the control group in Tidermark 2004 at
six months is not unexpected.
There was a lack of information on what constituted “standard re-
habilitation” in Sloan 1992, but the average length of hospital stay
in this trial is noticeably longer than that reported in a recent study
carried out in a nearby hospital (43 versus 24 days) in Vancou-
ver (Lefaivre 2009). Similarly, the prolonged treatment regimen
in both Hedstrom 2002 and Tidermark 2004 is not customary in
many countries.
The follow-up until discharge in Sloan 1992 resulted in bias be-
cause of the missing data for participants at the four-week time
point. The presentation of outcome data relating to dependence
was inadequate in all three trials. In Sloan 1992, this was reported
as a change in the level of care but it is unclear how permanent this
change was and what exactly this meant. Hedstrom 2002 provided
inadequate data to assess their conclusions, while Tidermark 2004
provided dichotomised data that may hide more subtle variation.
Side effects of anabolic steroids were reported in the three trials,
the most serious one occurring in a male patient in Sloan 1992.
These trials were too small to get any meaningful measure of the
harms of anabolic steroid treatment. However, Hedstrom 2002 re-
ported three participants with well known side effects (hoarseness
and facial hair) of anabolic steroids in females, and this points to
the importance of recording patient acceptability of this interven-
tion, which was not done in these trials.
Quality of the evidence
Overall, this review presents very low quality evidence for the ef-
fects of anabolic steroids for rehabilitation of hip fractures in older
people. Each of three small trials were at high risk of bias in one
or more domains evaluated in our assessment. Despite the use of
a placebo control group in Sloan 1992, there was a major baseline
imbalance in participant characteristics that could have affected
the findings of this trial. Post-randomisation exclusions and fail-
ure to follow-up patients after hospital discharge also reduces the
quality of the evidence on the use of anabolic steroids in the in-
patient setting. The two studies (Tidermark 2004 and Hedstrom
2002) that reported positive results, favouring the use of anabolic
steroid in combination with nutritional interventions, were not
adequately blinded as no placebo injections were given to the con-
trol group. The interaction between interventions could be re-
sponsible for the effects, or the effect could be solely attributed
to the nutritional intervention other than the anabolic steroid. As
well as downgrading for limitations in design and implementation
(risk of bias), we downgraded the evidence for imprecision (all
three trials) and publication bias (all three trials), reflecting the
very small numbers of published trials on this topic.
Potential biases in the review process
Although we conducted extensive searches and were careful and
systematic in our screening processes, it is possible that we may
have failed to identify studies, especially those that are unpub-
lished. Additionally, we may have missed published trials that are
only listed in other databases such as CINAHL and LILACS. We
were unsuccessful in our attempts to get further information and
data on the included trials. Deviations and changes from protocol
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described in Differences between protocol and review were few
and unlikely to bias the review findings.
Agreements and disagreements with other
studies or reviews
To our knowledge there have been no previous systematic re-
views on the use of anabolic steroids for recovery after hip fracture
surgery. There is some moderate quality evidence showing im-
proved outcomes in patients with hip fractures when nutritional
supplementation has been used (Avenell 2010), which points to
the importance of considering anabolic steroids as part of a pack-
age of interventions aimed at improving recovery. We have not
identified cohort studies monitoring the short-term or long-term
adverse effects of anabolic steroids in older people.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The available evidence is insufficient to draw conclusions on the ef-
fects, primarily in terms of functional outcome and adverse events,
of anabolic steroids, either separately or in combination with nu-
tritional supplements, after surgical treatment of hip fracture in
older people.
Implications for research
The importance of identifying effective and safe interventions, ap-
plied either alone or in combination, that improve the poor out-
come of people recovering from hip fracture continues. Further
randomised trials are warranted. As the available data from this
review points to the potential for more promising outcomes with
a combined anabolic steroid and nutritional supplement inter-
vention, we suggest that future research should focus on the use
of this combination. The potential toxicity of anabolic steroids
and adverse effects (particularly in females) is a barrier to further
research, and also deters clinicians from prescribing these drugs.
This points to the crucial need to collect data on adverse effects
and also on patient acceptability of the intervention.
One area that requires investigation is the effect of anabolic steroids
in male hip fracture patients who may have normal or low andro-
gen profiles. This is important, as even though the population is
smaller than female hip fractures, the outcomes after hip fracture
in males are worse.
Functional outcomes, such as independence in mobility and daily
activities, and monitoring of adverse events are important clinical
outcomes for older people who are recovering from hip fracture
and should be the primary outcomes of future hip fracture trials.
As recommended in Crotty 2010, a core set of functional out-
comes should be used in hip fracture trials with strict adherence to
reporting standards to obtain consistent data that allows for more
robust analysis in meta-analyses.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hedstrom 2002
Methods Randomised controlled trial
Participants 63 women (mean age 80.5 years) aged over 65 years who had been treated surgically
(internal fixation) for a hip fracture, living independently in their homes
Inclusion criteria: living independently in own home after hip fracture surgery, aged over
65 years
Exclusion criteria: treatment with bone active drugs; metabolic disease that could affect
the bone density; smoker; fracture of contralateral hip; cerebrovascular disease affecting
mobility; liver, thyroid or renal dysfunction; alcohol abuse; or dementia
Interventions Steroid group: nandrolone decanoate (25 mg intramuscular every 3 weeks) + 1alpha-
hydroxylated VitD3 (alphacalcidol 0.25 µg daily) + calcium (500 mg daily), N = 32
Control group: calcium only, N = 31
Intervention period: 12 months
Analysis: 25 versus 26 at 12 months, but see Notes
Outcomes Follow-up: assessments at 3, 6, 9 and 12 months (data from 6 and 12 months)
1. Katz index (activities of daily living)






8. Bone densitometry (not reported in review)
Setting Community setting, Danderyd, Sweden
Notes The numbers followed up at 6 and 12 months were provided but the group allocation
was unclear for two patients excluded because of ill health, and (although likely) whether
these were the same two patients excluded because of progressive cholangitis and primary
hyperparathyroidism, respectively. Additionally, seven patients followed for one year
who had arthroplasty for pseudarthrosis or avascular necrosis were not included in the
assessment of clinical function. Thus there is some uncertainty about the denominators
for these outcomes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of generating random sequences not described
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Hedstrom 2002 (Continued)
Allocation concealment (selection bias) Unclear risk “The patients were allocated by sealed envelopes to re-
ceive either treatment for one year with nandrolone de-
canoate (25 mg intramuscularly every third week), a daily
supplement of 1alpha-hydroxylated vitamin D3 (alpha-
calcidol 0.25 g) and calcium (500 mg), or to receive cal-
cium only”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not described
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not described
Incomplete outcome data (attrition bias)
All outcomes
High risk While drop-outs are described and numbers available at
follow-up are stated, there is a lack of clarity regarding
the exclusions of some participants (e.g. “Two patients
were subsequently excluded because of poor health”) and
numbers available for the clinical assessments. The au-
thors state that “the patients who discontinued treatment
were analysed by intention to treat, except for two who
were followed up for seven and eight months”. It is likely
that these were the same two patients, but it is not clear
Selective reporting (reporting bias) Unclear risk The method section does not describe a protocol for the
trial but all the outcomes mentioned in the methods sec-
tion were reported in the results. The method of report-
ing the results and whether there was an original inten-
tion to report results at 3 and 9 months was not clarified
Other bias Low risk No signs of baseline differences between the two groups.
The trial was carried out during the intended study period
with no early termination
Sloan 1992
Methods Randomised, double-blind, placebo-controlled pilot study
Participants 39 participants (31 female and 8 male) aged over 65 years treated surgically (internal
fixation or hemiarthoplasty) for hip fracture. The study reported characteristics of 29
females (mean age 82 years)
Inclusion criteria: “frail elderly” patients with hip fractures, written informed consent
obtained
Exclusion criteria: aged under 65, in extended care (highest level of nursing care) prior
to admission, had severe dementia impeding participation, severe medical illnesses, hor-
mone responsive conditions such as breast cancer or liver disease
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Sloan 1992 (Continued)
Interventions Steroid group: nandrolone decanoate (2 mg/kg weekly) + standard rehabilitation, N =
19
Control group: placebo + standard rehabilitation, N = 20
Intervention period for duration of hospital stay or until 4 weeks, whichever came first
Analysis: 15 versus 14 (females only)
Outcomes Follow-up: assessments weekly until 4 weeks or discharge, whichever came first
1. ’Rehabilitation end points’: days to weight-bear with support; days to mobilise inde-
pendently; length of hospital stay






Setting Inpatient setting, University Hospital Vancouver, Canada
Notes The study report presented detailed results for the female participants and a brief incom-
plete summary of the results for the male participants. We report only on the adverse
events for this second group
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process not described
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated double-blind: “Subjects were ran-
domized to therapy with either nandrolone
decanoate 2 mg/kg or placebo in a double-
blind fashion”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Stated double-blind: “Subjects were ran-
domized to therapy with either nandrolone
decanoate 2 mg/kg or placebo in a double-
blind fashion”
Incomplete outcome data (attrition bias)
All outcomes
High risk Drop-outs described: Two early with-
drawals (1 in the steroid group had ab-
normal liver function tests; 1 in the con-
trol group had nightmares) were excluded
from the analyses. Data from 10 out of
29 remaining participants were missing at
week four as these patients were discharged
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Sloan 1992 (Continued)
prior to the completion of this assessment;
there was an imbalance between the two
groups (12 versus 7) available for analysis
at 4 weeks
Selective reporting (reporting bias) Unclear risk The methods section does not describe any
pre-agreed protocol for the trial but all the
outcomes mentioned in the methods sec-
tion were reported in the results. It was not
clear that there was a prior intention to
present the full results only for the female
participants
Other bias High risk There was imbalance, based on recorded
activities of daily living scores, between
the groups in functional independence in
favour of the control group. The steroid
group tended to be lighter and have a lower
lean body mass
Tidermark 2004
Methods Randomised controlled trial
Participants 60 women (mean age 82.9 years) aged over 70 years treated surgically (internal fixation)
for an acute femoral neck fracture
Inclusion criteria: aged over 70 years, body mass index (BMI) less than or equal to 24
kg/m², without severe cognitive dysfunction, independent living status and independent
walking capability with or without walking aids
Exclusion criteria: fracture not suitable for internal fixation, i.e. pathological fractures
or were displaced fractures older than 24 hours at the time of arrival at the emergency
room; rheumatoid arthritis; or radiographic osteoarthritis
Interventions Steroid group: nandrolone decanoate (Deca-Durabol 25 mg every 3 weeks) + protein-
rich formula (Fortimel 200ml/day, 20 g protein/day) + daily calcium (1g) and vitamin
D (CalchichewD3 800 IE), N = 20
Protein supplementation group: protein-rich formula (Fortimel) + daily calcium + vita-
min D, N = 20
Control group: daily calcium and vitamin D, N = 20
Intervention period: 6 months
Analysis: 17 versus 18 versus 17 at 12 months
Outcomes Follow-up: assessments at 6 and 12 months
1. Katz index (activities of daily living)
2. EQ-5D
3. Mobility (data not shown in trial report)
4. Mortality
5. Fracture healing complications
6. Urinary tract infections
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9. Length of hospital stay
Setting Soder Hospital then in the community, Stockholm, Sweden
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Random sequence generation not described
Allocation concealment (selection bias) Low risk “The patients were randomised, using opaque, sealed en-
velopes, to open treatment during 6 months”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk The study was an open label study with no blinding of
participants. Of note, however, is that the research nurse
visited all patients “in order to minimise differences be-
tween treatments”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “A research nurse not involved in the surgery or clinical
decisions assessed all clinical variables.” No mention of
blinding, however
Incomplete outcome data (attrition bias)
All outcomes
Low risk Patient flowchart provided: “One patient in the PR/N
group withdrew her consent after inclusion and was ac-
cordingly excluded from the follow-up. Two patients
(3%) died and 5 (8%) were lost to follow-up, giving a
total of 52 out of 59 patients (88%) available at the final
follow-up (Fig. 1).” Intention-to-treat analysis not men-
tioned
Selective reporting (reporting bias) Unclear risk No description of protocol provided in the text of the
review but the outcomes mentioned in the methods sec-
tion were all reported in the results. Actual figures of the
Katz Index were not provided. Instead the results were di-
chotomised into functionally independent and function-
ally dependent groups and the results were presented as a
graph, which makes it impossible to pool results in meta-
analysis. EQ-5D scores were also presented as graph only
using linear regression. No mean scores or mean change
scores were provided. Posthoc analysis was performed but
was not intended and it was published separately
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Tidermark 2004 (Continued)
Other bias Low risk No signs of baseline differences among the groups and
no signs of early termination of the trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beringer 1986 The focus of this study was on the role of calcitonin in the aetiology of postmenopausal osteoporosis. The comparison,
anabolic steroid versus calcium, did not meet the inclusion criteria in the review
Naessen 2008 The focus of this study was postural balance function in older women. However, the study population was healthy
females with no hip fracture; i.e. wrong population
Characteristics of ongoing studies [ordered by study ID]
NCT00280267
Trial name or title Testosterone therapy after hip fracture in elderly women
Methods Randomised, double-blinded, placebo-controlled prospective study to determine the feasibility, tolerability
and safety of six months of testosterone therapy in community-dwelling, physically frail, elderly female hip
fracture patients
Participants Planned recruitment: 27 female hip fracture patients, using objective criteria for testosterone deficiency and
frailty
Interventions Evaluate two dosages of testosterone, administered as a 0.5% topical gel: a supraphysiologic dosage versus
physiologic replacement dosage
Outcomes Primary outcomes: serum testosterone levels, drug compliance, symptoms and side effects during the six
months of treatment
Secondary outcomes:
• Modified Physical Performance Test Score at 6 months
• 1-RM muscle strength at 6 months
• Thigh cross-sectional area by MRI (magnetic resonance imaging) at 6 months
• Self-report of ADL (activities of daily living) function at 6 months
• SF-36 score (quality of life) at 6 months
• Total and regional bone density by DEXA (dual energy X-ray absorptiometry) at 6 months
Starting date Start date: August 2004
Contact information Ellen F. Binder, Washington University School of Medicine, Division of Geriatrics and Nutritional Science
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NCT00280267 (Continued)
Notes Completed: December 2006
The author was contacted via email and has confirmed that the data are still unpublished. Results were
requested but have not been provided by the author
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D A T A A N D A N A L Y S E S
Comparison 1. Anabolic steroids versus control




participants Statistical method Effect size
1 More dependent or dead at
hospital discharge
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Dependence in bathing and
one more function (Katz ADL
index) or dead
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 At 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Mobility (inpatient) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Days to weight-bear with
support
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Days to mobilise
independently
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Mortality 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 In hospital 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 At 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse events 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Fracture healing
complications
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Urinary track infection 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Thrombotic complication
(deep vein thrombosis or
pulmonary embolism)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Gastrointestinal bleed 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.5 Postoperative depression 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.6 Postoperative delirium 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Body composition at 4 weeks
follow-up
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Weight (kg) (higher values
suggest better outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Midarm muscle
circumference (cm²) (higher
values suggest better outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Lean body mass measured
by subscapular skinfold (kg)
(higher values suggest better
outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Lean body mass via
bioelectric impedence (kg)
(higher values suggest better
outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Body composition at 12 months
follow-up
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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7.1 Weight (kg): difference
from baseline (higher values
suggest better outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Lean body mass by dual
energy X-ray absorptiometry
(kg) difference from baseline
(higher values suggest better
outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Nutritional indices 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Albumin (g/L) at 4 weeks
(higher values suggest better
outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Albumin (g/L) change
from baseline at 12 months
(higher values suggest better
outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 Haemoglobin (g/L) at 4
weeks (higher values suggest
better outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Muscle strength 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Grip strength (modified
sphygmomanometer (kPa)) at
4 weeks
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 Grip strength (hand grip
dynamometer (kg)); difference
from baseline at 12 months
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Length of hospital stay (days) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Anabolic steroids with other intervention versus control




participants Statistical method Effect size
1 Katz index of ADL (Score 0 to
6; 6 = completely independent,
0 = totally dependent)
Other data No numeric data
2 Dependence in bathing and
one more function (Katz ADL
index) or dead
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 At 6 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 12 months 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Harris hip score (100 point scale;
higher score = better outcome)
Other data No numeric data
4 Gait speed (s/30m) Other data No numeric data
5 Mortality (12 months) 2 102 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.15, 3.46]
6 Adverse events 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Arthroplasty for avascular
necrosis or pseudarthrosis
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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6.2 Side effects of anabolic
steroids
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Fracture healing
complications
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Deep infection 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.5 Urinary track infection 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Body composition Other data No numeric data
7.1 BMI (kg/m²) Other data No numeric data
7.2 Muscle volume operated
leg (cm²)
Other data No numeric data
7.3 Muscle volume
non-operated leg (cm²)
Other data No numeric data
7.4 Relative muscle mass
operated leg (cm²)
Other data No numeric data
7.5 Relative muscle mass
non-operated leg (cm²)
Other data No numeric data
7.6 Triceps skinfold (mm) Other data No numeric data
8 Body composition at 12 months
follow-up
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Weight (kg): difference
from baseline (higher values
suggest better outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 Lean body mass by dual
energy X-ray absorptiometry
(kg) difference from baseline
(higher values suggest better
outcome)
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Nutritional indices: albumin
(g/L) change from baseline
at 12 months (higher values
suggest better outcome)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10 Muscle strength: grip strength
(hand grip dynamometer (kg));
difference from baseline at 12
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Anabolic steroids versus control, Outcome 1 More dependent or dead at
hospital discharge.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 1 More dependent or dead at hospital discharge
Study or subgroup Anabolic steroid Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sloan 1992 (1) 8/15 10/14 0.75 [ 0.42, 1.33 ]
0.2 0.5 1 2 5
Favours steroid Favours control
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(1) 8 versus 9 were discharged to a higher level of care; 1 died in the control group
Analysis 1.2. Comparison 1 Anabolic steroids versus control, Outcome 2 Dependence in bathing and one
more function (Katz ADL index) or dead.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 2 Dependence in bathing and one more function (Katz ADL index) or dead
Study or subgroup Anabolic steroid Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 6 months
Tidermark 2004 0/17 3/19 0.16 [ 0.01, 2.87 ]
2 At 12 months
Tidermark 2004 1/17 5/19 0.22 [ 0.03, 1.73 ]
0.002 0.1 1 10 500
Favours steroid Favours control
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Analysis 1.3. Comparison 1 Anabolic steroids versus control, Outcome 3 Mobility (inpatient).
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 3 Mobility (inpatient)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Days to weight-bear with support
Sloan 1992 15 3.1 (2.4) 14 2.3 (1.3) 0.80 [ -0.59, 2.19 ]
2 Days to mobilise independently
Sloan 1992 15 14.5 (11.1) 14 9.3 (7.6) 5.20 [ -1.68, 12.08 ]
-10 -5 0 5 10
Favours steroid Favours control
Analysis 1.4. Comparison 1 Anabolic steroids versus control, Outcome 4 Mortality.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 4 Mortality
Study or subgroup Anabolic steroid Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 In hospital
Sloan 1992 0/15 1/14 0.31 [ 0.01, 7.09 ]
2 At 12 months
Tidermark 2004 0/19 1/20 0.35 [ 0.02, 8.10 ]
0.01 0.1 1 10 100
Favours steroid Favours control
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Analysis 1.5. Comparison 1 Anabolic steroids versus control, Outcome 5 Adverse events.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 5 Adverse events
Study or subgroup Anabolic steroid Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fracture healing complications
Tidermark 2004 6/19 4/20 1.58 [ 0.53, 4.74 ]
2 Urinary track infection
Tidermark 2004 5/19 3/20 1.75 [ 0.48, 6.35 ]
3 Thrombotic complication (deep vein thrombosis or pulmonary embolism)
Sloan 1992 (1) 1/15 1/14 0.93 [ 0.06, 13.54 ]
4 Gastrointestinal bleed
Sloan 1992 0/15 1/14 0.31 [ 0.01, 7.09 ]
5 Postoperative depression
Sloan 1992 0/15 2/14 0.19 [ 0.01, 3.60 ]
6 Postoperative delirium
Sloan 1992 2/15 0/14 4.69 [ 0.24, 89.88 ]
0.002 0.1 1 10 500
Favours steroid Favours control
(1) Steroid: PE; Control: DVT
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Analysis 1.6. Comparison 1 Anabolic steroids versus control, Outcome 6 Body composition at 4 weeks
follow-up.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 6 Body composition at 4 weeks follow-up





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Weight (kg) (higher values suggest better outcome)
Sloan 1992 12 53.6 (6.8) 7 59.8 (7.8) -6.20 [ -13.14, 0.74 ]
2 Midarm muscle circumference (cm2) (higher values suggest better outcome)
Sloan 1992 12 35.1 (4.2) 7 41.1 (18.5) -6.00 [ -19.91, 7.91 ]
3 Lean body mass measured by subscapular skinfold (kg) (higher values suggest better outcome)
Sloan 1992 12 36.7 (3.8) 7 40.1 (5.5) -3.40 [ -8.01, 1.21 ]
4 Lean body mass via bioelectric impedence (kg) (higher values suggest better outcome)
Sloan 1992 12 30.6 (3.2) 7 31.5 (4.8) -0.90 [ -4.89, 3.09 ]
-20 -10 0 10 20
Favours control Favours steroid
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Analysis 1.7. Comparison 1 Anabolic steroids versus control, Outcome 7 Body composition at 12 months
follow-up.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 7 Body composition at 12 months follow-up





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Weight (kg): difference from baseline (higher values suggest better outcome)
Tidermark 2004 17 -1.28 (1.7) 18 -1.82 (4.7) 0.54 [ -1.78, 2.86 ]
2 Lean body mass by dual energy X-ray absorptiometry (kg) difference from baseline (higher values suggest better outcome)
Tidermark 2004 17 -0.69 (2) 18 -1.57 (1.5) 0.88 [ -0.30, 2.06 ]
-2 -1 0 1 2
Favours control Favours steroid
Analysis 1.8. Comparison 1 Anabolic steroids versus control, Outcome 8 Nutritional indices.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 8 Nutritional indices





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Albumin (g/L) at 4 weeks (higher values suggest better outcome)
Sloan 1992 12 30 (4) 7 31 (3) -1.00 [ -4.17, 2.17 ]
2 Albumin (g/L) change from baseline at 12 months (higher values suggest better outcome)
Tidermark 2004 17 7.2 (4.4) 18 6.9 (5.4) 0.30 [ -2.96, 3.56 ]
3 Haemoglobin (g/L) at 4 weeks (higher values suggest better outcome)
Sloan 1992 12 114 (10) 7 110 (20) 4.00 [ -11.86, 19.86 ]
-20 -10 0 10 20
Favours control Favours steroid
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Analysis 1.9. Comparison 1 Anabolic steroids versus control, Outcome 9 Muscle strength.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 9 Muscle strength





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Grip strength (modified sphygmomanometer (kPa)) at 4 weeks
Sloan 1992 12 23 (12) 7 25 (11) -2.00 [ -12.61, 8.61 ]
2 Grip strength (hand grip dynamometer (kg)); difference from baseline at 12 months
Tidermark 2004 17 0.8 (3.5) 18 0.73 (3) 0.07 [ -2.10, 2.24 ]
-10 -5 0 5 10
Favours control Favours steroid
Analysis 1.10. Comparison 1 Anabolic steroids versus control, Outcome 10 Length of hospital stay (days).
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 1 Anabolic steroids versus control
Outcome: 10 Length of hospital stay (days)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sloan 1992 15 45 (21) 14 40 (24) 5.00 [ -11.46, 21.46 ]
-100 -50 0 50 100
Favours steroid Favours control
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Analysis 2.1. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 1 Katz
index of ADL (Score 0 to 6; 6 = completely independent, 0 = totally dependent).
Katz index of ADL (Score 0 to 6; 6 = completely independent, 0 = totally dependent)
Study Assessment
(best estimate N given)
Steroid plus nutrition
group
Control group Reported P value
Hedstrom 2002 6 months: median (range)
; N
6 (5 to 6); N = 26 6 (5 to 6); N = 24 0.7
Hedstrom 2002 12 months: median
(range); N
6 (5 to 6); N = 21 6 (2 to 6); N = 23 0.05
Analysis 2.2. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 2
Dependence in bathing and one more function (Katz ADL index) or dead.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 2 Anabolic steroids with other intervention versus control
Outcome: 2 Dependence in bathing and one more function (Katz ADL index) or dead
Study or subgroup Steroid plus nutrition Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At 6 months
Tidermark 2004 0/17 8/16 0.06 [ 0.00, 0.89 ]
2 At 12 months
Tidermark 2004 1/17 7/18 0.15 [ 0.02, 1.10 ]
0.002 0.1 1 10 500
Favours steroid plus Favours control
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Analysis 2.3. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 3 Harris hip
score (100 point scale; higher score = better outcome).
Harris hip score (100 point scale; higher score = better outcome)
Study Assessment
(best estimate N given)
Steroid plus nutrition
group
Control group Reported P value
Hedstrom 2002 6 months: median (range)
; N
86 (59 to 100); N = 26 72 (42 to 91); N = 24 0.006
Hedstrom 2002 12 months: median
(range); N
88.5 (64 to 100); N = 21 79 (48 to 98); N = 23 0.04




(best estimate N given)
Steroid plus nutrition
group
Control group Reported P value
Hedstrom 2002 6 months: median (range)
; N
34 (20 to 70); N = 26 50 (20 to 145); N = 24 0.007
Hedstrom 2002 12 months: median
(range); N
30 (20 to 90); N = 21 46 (25 to 250); N = 23 0.009
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Analysis 2.5. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 5 Mortality
(12 months).
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 2 Anabolic steroids with other intervention versus control
Outcome: 5 Mortality (12 months)
Study or subgroup Steroid plus nutrition Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hedstrom 2002 2/32 2/31 58.1 % 0.97 [ 0.15, 6.46 ]
Tidermark 2004 0/19 1/20 41.9 % 0.35 [ 0.02, 8.10 ]
Total (95% CI) 51 51 100.0 % 0.71 [ 0.15, 3.46 ]
Total events: 2 (Steroid plus nutrition), 3 (Control)
Heterogeneity: Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours steroid plus Favours control
Analysis 2.6. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 6 Adverse
events.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 2 Anabolic steroids with other intervention versus control
Outcome: 6 Adverse events
Study or subgroup Steroid plus nutrition Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Arthroplasty for avascular necrosis or pseudarthrosis
Hedstrom 2002 4/32 3/31 1.29 [ 0.31, 5.31 ]
2 Side effects of anabolic steroids
Hedstrom 2002 (1) 3/32 0/31 6.79 [ 0.36, 126.24 ]
3 Fracture healing complications
Tidermark 2004 6/19 7/20 0.90 [ 0.37, 2.20 ]
4 Deep infection
Tidermark 2004 2/19 0/20 5.25 [ 0.27, 102.74 ]
5 Urinary track infection
Tidermark 2004 5/19 3/20 1.75 [ 0.48, 6.35 ]
0.01 0.1 1 10 100
Favours steroid plus Favours control
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(1) Hoarseness or increased facial hair
Analysis 2.7. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 7 Body
composition.
Body composition
Study Assessment Steroid plus nutrition
group
Control group Reported P value
BMI (kg/m²) BMI (kg/m²)
Hedstrom 2002 6 months: mean change -1.3 -1.0 “NS” (> 0.05)
Hedstrom 2002 12 months: mean change -1.6 -0.5 “NS” (> 0.05)
Muscle volume operated leg (cm²) Muscle volume operated
Hedstrom 2002 6 months: mean change -0.1 -7.1 0.01
Hedstrom 2002 12 months: mean change 3 -6.3 0.01
Muscle volume non-operated leg (cm²) Muscle volume non-operated
Hedstrom 2002 6 months: mean change 12.6 8.6 0.004
Hedstrom 2002 12 months: mean change 14.1 8.1 0.002
Relative muscle mass operated leg (cm²) Relative muscle
Hedstrom 2002 6 months: mean change 339 -25 0.03
Hedstrom 2002 12 months: mean change 617 -161 0.002
Relative muscle mass non-operated leg (cm²) Relative muscle mass
Hedstrom 2002 6 months: mean change 836 573 0.02
Hedstrom 2002 12 months: mean change 1049 434 0.0005
Triceps skinfold (mm) Triceps skinfold
Hedstrom 2002 6 months: mean change -1.6 0.5 0.04
Hedstrom 2002 12 months: mean change -1.6 0.6 “NS” (> 0.05)
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Analysis 2.8. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 8 Body
composition at 12 months follow-up.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 2 Anabolic steroids with other intervention versus control
Outcome: 8 Body composition at 12 months follow-up





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Weight (kg): difference from baseline (higher values suggest better outcome)
Tidermark 2004 17 -1.28 (1.7) 17 -1.55 (3.3) 0.27 [ -1.49, 2.03 ]
2 Lean body mass by dual energy X-ray absorptiometry (kg) difference from baseline (higher values suggest better outcome)
Tidermark 2004 17 -0.69 (2) 17 -1.11 (1.7) 0.42 [ -0.83, 1.67 ]
-2 -1 0 1 2
Favours control Favours steroid plus
Analysis 2.9. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 9
Nutritional indices: albumin (g/L) change from baseline at 12 months (higher values suggest better outcome).
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 2 Anabolic steroids with other intervention versus control
Outcome: 9 Nutritional indices: albumin (g/L) change from baseline at 12 months (higher values suggest better outcome)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tidermark 2004 17 7.2 (4.4) 17 3.8 (8.2) 3.40 [ -1.02, 7.82 ]
-20 -10 0 10 20
Favours control Favours steroid plus
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Analysis 2.10. Comparison 2 Anabolic steroids with other intervention versus control, Outcome 10 Muscle
strength: grip strength (hand grip dynamometer (kg)); difference from baseline at 12 months.
Review: Anabolic steroids for rehabilitation after hip fracture in older people
Comparison: 2 Anabolic steroids with other intervention versus control
Outcome: 10 Muscle strength: grip strength (hand grip dynamometer (kg)); difference from baseline at 12 months





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Tidermark 2004 17 0.8 (3.5) 17 -0.88 (3.5) 1.68 [ -0.67, 4.03 ]
-10 -5 0 5 10
Favours control Favours steroid plus
A D D I T I O N A L T A B L E S
Table 1. Demographics of included participants




























All study participants described above were females. However, no other details and very limited results were provided for eight male
participants in Sloan 1992
BMI: body mass index
SD: standard deviation
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Central Register of Controlled Trials (Wiley Online Library)
#1 MeSH descriptor: [Femoral Fractures] explode all trees (1184)
#2 ((hip* or pertrochant* or intertrochant* or trochanteric or subtrochanteric or extracapsular* or ((femur* or femoral*) near/3 (neck
or proximal or head))) near/4 fracture*) (2541)
#3 #1 or #2 (2659)
#4 MeSH descriptor: [Steroids] explode all trees (36182)
#5 MeSH descriptor: [Androgens] explode all trees (526)
#6 MeSH descriptor: [Anabolic Agents] explode all trees (259)
#7 anabolic near/1 steroid* (227)
#8 androgen* near/1 anabolic (58)
#9 etiocholanolone or androst* or prasterone or stanolone or testosterone or methyltestosterone or metribolone or ethylestrenol
or fluoxymesterone or mesterolone or methandriol or methandrostenolone or methenolone or nandrolone or norethandrolone or
oxandrolone or oxymetholone or stanozolol or trenbolone or amafolone or atromid or benorterone or boldenone or calusterone or
danazol or drostanolone or etiocholanone or mestanolone or mibolerone or testololactone or hydroxyandrost* or epiandrosterone or
oxotestosterone or oxoandrostenedione (6312)
#10 #4 or #5 or #6 or #7 or #8 or #9 (37878)
#11 #3 and #10 in Trials (113)
MEDLINE (OvidSP)
1 exp Femoral Fractures/ (29353)
2 ((hip* or pertrochant* or intertrochant* or trochanteric or subtrochanteric or extracapsular* or ((femur* or femoral*) adj3 (neck or
proximal or head))) adj4 fracture*).mp. (25085)
3 1 or 2 (35370)
4 exp Steroids/ (710010)
5 exp Androgens/ (82963)
6 exp Anabolic Agents/ (12095)
7 (anabolic adj1 steroid*).mp. (3830)
8 (androgen* adj1 anabolic).mp. (1261)
9 (etiocholanolone or androst* or prasterone or stanolone or testosterone or methyltestosterone or metribolone or ethylestrenol or
fluoxymesterone or mesterolone or methandriol or methandrostenolone or methenolone or nandrolone or norethandrolone or oxan-
drolone or oxymetholone or stanozolol or trenbolone or amafolone or atromid or benorterone or boldenone or calusterone or danazol
or drostanolone or etiocholanone or mestanolone or mibolerone or testololactone or hydroxyandrost* or epiandrosterone or oxotestos-
terone or oxoandrostenedione).mp. (112744)
10 or/4-9 (742213)
11 3 and 10 (1155)
12 Randomized controlled trial.pt. (384981)
13 Controlled clinical trial.pt. (89120)
14 randomized.ab. (300266)
15 placebo.ab. (161737)





21 exp Animals/ not Humans/ (4027008)
22 20 not 21 (2899484)
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23 11 and 22 (598)
EMBASE (OvidSP)
1 exp Hip Fracture/ (28832)
2 ((hip* or pertrochant* or intertrochant* or trochanteric or subtrochanteric or extracapsular* or ((femur* or femoral*) adj3 (neck or
proximal or head))) adj4 fracture*).mp. (37173)
3 1 or 2 (38355)
4 exp Steroid Therapy/ (65380)
5 exp Androgen/ (147750)
6 exp Anabolic Agent/ (22104)
7 (anabolic adj1 steroid*).mp. (4260)
8 (androgen* adj1 anabolic).mp. (1507)
9 (etiocholanolone or androst* or prasterone or stanolone or testosterone or methyltestosterone or metribolone or ethylestrenol or
fluoxymesterone or mesterolone or methandriol or methandrostenolone or methenolone or nandrolone or norethandrolone or oxan-
drolone or oxymetholone or stanozolol or trenbolone or amafolone or atromid or benorterone or boldenone or calusterone or danazol
or drostanolone or etiocholanone or mestanolone or mibolerone or testololactone or hydroxyandrost* or epiandrosterone or oxotestos-
terone or oxoandrostenedione).mp. (156319)
10 or/4-9 (245815)
11 3 and 10 (1234)
12 Randomized controlled trial/ (357881)
13 Clinical trial/ (892653)
14 Controlled clinical trial/ (405007)
15 Randomization/ (63369)
16 Single blind procedure/ (18204)
17 Double blind procedure/ (119927)
18 Crossover procedure/ (38360)
19 Placebo/ (237582)
20 Prospective study/ (248905)
21 ((clinical or controlled or comparative or placebo or prospective* or randomi#ed) adj3 (trial or study)).tw. (738968)
22 (random* adj7 (allocat* or allot* or assign* or basis* or divid* or order*)).tw. (178166)
23 ((singl* or doubl* or trebl* or tripl*) adj7 (blind* or mask*)).tw. (165101)
24 (cross?over* or (cross adj1 over*)).tw. (70352)




28 Case Study/ or Abstract Report/ or Letter/ (924227)
29 27 not 28 (1863905)
30 11 and 29 (480)
WHO International Clinical Trials Registry Platform
Advanced search option
Condition: hip% OR femur% OR femoral
Intervention: anabolic OR steroid% OR androgen OR etiocholanolone OR androst% OR prasterone OR stanolone OR testosterone OR
methyltestosterone OR metribolone OR ethylestrenol OR fluoxymesterone OR mesterolone OR methandriol OR methandrostenolone
OR methenolone OR nandrolone OR nORethandrolone OR oxandrolone OR oxymetholone OR stanozolol OR trenbolone OR
amafolone OR atromid OR benORterone OR boldenone OR calusterone OR danazol OR drostanolone OR etiocholanone OR mes-
tanolone OR mibolerone OR testololactone OR hydroxyandrost% OR epiandrosterone OR oxotestosterone OR oxoandrostenedione
Recruitment status: all
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Current Controlled Trial
(femoral OR femur OR hip OR hips) AND (fracture OR fractures) AND (anabolic ) [All Registers]
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
1. The Background was updated with the addition of more up-to-date supporting references.
2. In our risk of bias assessment we split the blinding domain into two as per updated guidance (Higgins 2011). Contrary to our
intentions implied in our protocol, we assessed risk of bias associated with blinding and incomplete outcome data for all outcomes
together rather than separately by individual or the main classes of outcomes.
3. The limited data available from Sloan 1992 meant that we were unable to analyse the impact of drop-outs on the final result and
to adjust results by conducting worst- or best-case scenario sensitivity analysis.
4. We clarified the basis for interpreting I² values in Assessment of heterogeneity.
5. We used the GRADE approach to assess the quality of evidence.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anabolic Agents [adverse effects; ∗therapeutic use]; Androgens [adverse effects; ∗therapeutic use]; Frail Elderly; Hip Fractures
[∗rehabilitation; surgery]; Nandrolone [adverse effects; ∗analogs & derivatives; therapeutic use]; Postoperative Care [methods]; Quality
of Life; Randomized Controlled Trials as Topic
MeSH check words
Aged; Aged, 80 and over; Female; Humans; Male
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